Neurodegenerative Diseases: current treatment algorithm and potential investment opportunities covered in a lates research report

This report examines the entire neurodegenerative disease therapy area, with a particular focus on the three most prevalent neurodegenerative disorders: Alzheimer’s disease (AD), Parkinson’s disease (PD) and multiple sclerosis (MS).

Pune, India - March 14, 2018 /MarketersMedia/ —

AD and PD represent the most pressing challenges within the disease cluster, due to rapidly increasing prevalence driven by aging populations. Both AD and PD remain ineffectively treated despite substantial investment into R&D by pharmaceutical companies, due to high clinical trial failure rates. As a result there are no disease-modifying therapies for these two indications, with available treatments able to provide only marginal symptomatic relief. MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic, and has a lucrative pharmacological market following breakthrough success in the past decade.
Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-neurodegenerative-diseases-protein-misfolding-targets-and-neuromodulators-dominate-the-first-in-class-pipeline-and-lead-the-way-as-potential-disease-modifying-therapies-in-ad-and-pd
Reasons To Buy
• Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
• Identify leading products and key unmet needs within the market.
• Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets categorized into four major classes: protein misfolding, neuromodulators, immunomodulators and neuroprotectants. The most promising first-in-class targets are reviewed in greater detail.
• Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.
Get this report at: https://www.themarketreports.com/report/buy-now/935553
Scope
• Unmet need is extremely high in AD and PD, with MS showing continued promise in the development of effective therapies
• What are the most important etiological risk factors and pathophysiological processes implicated in AD, PD and MS?
• What is the current treatment algorithm?
• How effective are current therapies for these indications, and how does this impact prognosis?
• The AD pipeline is large and contains a very high proportion of first-in-class product innovation.
• Which molecule types and molecular targets are most prominent across AD, PD and MS?
• What are the connections, in terms of first-in-class innovation, between AD, PD and MS?
• Which first-in-class targets are most promising?
Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935553

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/neurodegenerative-diseases-current-treatment-algorithm-and-potential-investment-opportunities-covered-in-a-lates-research-report/314330

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-neurodegenerative-diseases-protein-misfolding-targets-and-neuromodulators-dominate-the-first-in-class-pipeline-and-lead-the-way-as-potential-disease-modifying-therapies-in-ad-and-pd%20

Source: MarketersMedia

Release ID: 314330

Latest News

Lawmakers seek investigation of Interior boss' land deal

Jun 21, 2018

BILLINGS, Mont. — Democratic lawmakers called for an investigation Thursday into U.S. Interior Secretary Ryan Zinke's involvement in a land deal with the chairman of an energy services company that does business with his agency. A foundation created by Zinke and run by his wife, Lola, has been dealing with a company co-owned by Halliburton Chairman David Lesar on a commercial development in Whitefish, Montana — Zinke's hometown. The foundation is allowing Lesar and his family to use a portion of its land as a parking lot for the development. The land was donated to Zinke's Great Northern Veterans Peace...

Fed finds biggest US banks strong enough to survive shock

Jun 21, 2018

WASHINGTON — The Federal Reserve says that all of the 35 largest U.S. banks are fortified enough to survive an economic shock and keep on lending. Banks' hypothetical losses from credit cards increased in the latest "stress tests," however. The first round of the central bank's annual stress tests, released Thursday, shows that as a group, the 35 big banks have benefited from a steadily recovering economy to gain strength and build up capital buffers against unexpected losses. It was the eighth annual check-up for the banks, mandated by Congress after the 2008 financial crisis that triggered the Great Recession....

What's that extra in my online cart? Soon, maybe a sales tax

Jun 21, 2018

NEW YORK — Attention shoppers: You may soon be paying more taxes on what you put in your online cart. The Supreme Court ruled Thursday that states can require online retailers to collect sales tax on purchases that come from states where they don't have any shops, offices or warehouses. Before that, retailers didn't have to collect state sales taxes if it was shipping items to someone in a state where the business didn't have a physical presence. Shoppers were generally supposed to pay the sales tax to the state themselves, but most didn't, says Gerald Storch, who was CEO...

US stocks skid as industrials, automakers, tech trade lower

Jun 21, 2018

NEW YORK — Car makers and technology and industrial companies fell Thursday as investors focused on the U.S.-China trade dispute, which could reduce company spending and earnings. The Dow Jones Industrial Average slipped for the eighth day in a row. While investors generally don't expect a trade war between the U.S. and China, they remain sensitive to signs that rising tariffs and trade tensions will hurt the global economy and reduce corporate profits. This week they've received some signs that this is happening. On Thursday German automaker Daimler said the tariffs China plans to put on cars imported from the...

Trump jabbed first, and now world hits back in trade fight

Jun 21, 2018

WASHINGTON — The United States attacked first, imposing tariffs on steel and aluminum from around the globe and threatening to hit tens of billions of dollars in Chinese products. Now, the world is punching back. The European Union is set Friday to slap tariffs on $3.4 billion in American products, from whiskey and motorcycles to peanuts and cranberries. India and Turkey have already targeted U.S. products, ranging from rice to autos to sunscreen. And the highest-stakes fight still looms: In two weeks, the United States is to start taxing $34 billion in Chinese goods. Beijing has vowed to immediately retaliate...

Search
Financial Markets

About Us

Established in 2015, The Upstocker provides insights on financial reports, commentary, and investment data to traders so that you can make better investment decisions.

Contact us: sales[at]theupstocker.com

Subscribe Now!